MX2022012384A - Composiciones y metodos para cribar mutaciones en el cancer de tiroides. - Google Patents

Composiciones y metodos para cribar mutaciones en el cancer de tiroides.

Info

Publication number
MX2022012384A
MX2022012384A MX2022012384A MX2022012384A MX2022012384A MX 2022012384 A MX2022012384 A MX 2022012384A MX 2022012384 A MX2022012384 A MX 2022012384A MX 2022012384 A MX2022012384 A MX 2022012384A MX 2022012384 A MX2022012384 A MX 2022012384A
Authority
MX
Mexico
Prior art keywords
methods
thyroid cancer
compositions
screening
patient
Prior art date
Application number
MX2022012384A
Other languages
English (en)
Inventor
Kevin Qu
Joseph J Catanese
Andrew Grupe
Feras Hantash
Frederic M Waldman
Shih-Min Cheng
Original Assignee
Quest Diagnostics Invest Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quest Diagnostics Invest Llc filed Critical Quest Diagnostics Invest Llc
Publication of MX2022012384A publication Critical patent/MX2022012384A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1068—Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

La presente tecnología se refiere a métodos para determinar si un paciente que tiene nódulos tiroideos con citología indeterminada se beneficiará de una cirugía diagnostica, por ejemplo, lobectomía. Estos métodos se basan en el cribado de los nódulos tiroideos de un paciente y la detección de alteraciones en las secuencias de ácido nucleicos diana que corresponden a una serie específica de genes relacionados con el cáncer de tiroides. También se proveen kits para usarse en la práctica de los métodos.
MX2022012384A 2015-12-31 2018-06-29 Composiciones y metodos para cribar mutaciones en el cancer de tiroides. MX2022012384A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562273783P 2015-12-31 2015-12-31
US201662439572P 2016-12-28 2016-12-28

Publications (1)

Publication Number Publication Date
MX2022012384A true MX2022012384A (es) 2023-01-16

Family

ID=59225391

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018008197A MX2018008197A (es) 2015-12-31 2016-12-30 Composiciones y metodos para cribar mutaciones en el cancer de tiroides.
MX2022012384A MX2022012384A (es) 2015-12-31 2018-06-29 Composiciones y metodos para cribar mutaciones en el cancer de tiroides.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018008197A MX2018008197A (es) 2015-12-31 2016-12-30 Composiciones y metodos para cribar mutaciones en el cancer de tiroides.

Country Status (7)

Country Link
US (2) US11053542B2 (es)
EP (2) EP3397766B1 (es)
CN (1) CN108699553B (es)
BR (1) BR112018013430A2 (es)
CA (1) CA3010013A1 (es)
MX (2) MX2018008197A (es)
WO (1) WO2017117523A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107937986A (zh) * 2017-11-10 2018-04-20 深圳裕策生物科技有限公司 一种ffpe dna建库用试剂盒、其用途及建库方法
CN109371139A (zh) * 2018-12-29 2019-02-22 杭州迪安医学检验中心有限公司 一种基于高通量测序技术用于检测甲状腺癌致病相关基因变异的引物及其应用
CN109652535A (zh) * 2019-01-30 2019-04-19 上海安甲生物科技有限公司 鉴别人甲状腺结节良恶性的试剂盒及其使用方法和应用
US20210010060A1 (en) * 2019-07-02 2021-01-14 Genenius Genetics Highly Multiplexed PCR with Bioinformatically Optimized Primers to Prepare Targeted Libraries for Next-Generation Sequencing
CN110241215B (zh) * 2019-07-03 2020-05-19 上海润安医学科技有限公司 一种用于检测甲状腺结节良恶性相关基因变异的引物及试剂盒
IT201900024009A1 (it) * 2019-12-13 2021-06-13 Univ Degli Studi Roma La Sapienza Nuovo procedimento per la diagnosi di un tumore tiroideo e relativo kit
CN110878358B (zh) * 2019-12-19 2020-08-25 上海宝藤生物医药科技股份有限公司 一组甲状腺癌标志物及其应用
CN112080566B (zh) * 2020-08-25 2021-08-17 上海交通大学医学院附属瑞金医院 基于高通量测序法的甲状腺癌检测产品及用途
CN112011615A (zh) * 2020-09-01 2020-12-01 上海睿璟生物科技有限公司 用于人甲状腺癌基因融合试剂盒及检测方法
CN111979327A (zh) * 2020-09-01 2020-11-24 上海睿璟生物科技有限公司 用于人甲状腺免提取癌基因突变检测试剂盒及检测方法
CN114277115A (zh) * 2020-09-27 2022-04-05 上海鹍远生物科技股份有限公司 甲状腺结节良恶性相关标志物及其应用
CN113176408B (zh) * 2021-06-02 2022-10-11 四川大学华西医院 一种甲状腺癌预后情况判断的方法
CN117286247A (zh) * 2022-09-07 2023-12-26 上海医创云康生物科技有限公司 一种甲状腺基因检测试剂盒

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795762A (en) 1986-08-22 1998-08-18 Roche Molecular Systems, Inc. 5' to 3' exonuclease mutations of thermostable DNA polymerases
US5466591A (en) 1986-08-22 1995-11-14 Hoffmann-La Roche Inc. 5' to 3' exonuclease mutations of thermostable DNA polymerases
JPH06502303A (ja) 1990-10-05 1994-03-17 バーネス，ウェーン・エム 熱安定性ｄｎａポリメラーゼ
US20070154915A1 (en) * 2005-11-04 2007-07-05 Johji Inazawa Method for detecting cancer and a method for suppressing cancer
CA2557134A1 (en) * 2006-08-23 2008-02-23 National Research Council Of Canada Molecular method for diagnosis of colon cancer
CN102325905B (zh) * 2009-03-13 2014-07-16 株式会社益力多本社 伊立替康的敏感性判断方法及其利用
US8980554B2 (en) * 2010-07-26 2015-03-17 The Johns Hopkins University Genetic make-up modifies cancer outcome
GB201017011D0 (en) * 2010-10-08 2010-11-24 Skova Services Ltd Assay
EP2505664B1 (en) * 2011-03-30 2014-12-03 Universität Leipzig Method and means for distinguishing malignant from benign tumor samples, in particular in routine air dried fine needle aspiration biopsy (FNAB)
EP2771487A1 (en) 2011-10-27 2014-09-03 Asuragen, INC. Mirnas as diagnostic biomarkers to distinguish benign from malignant thyroid tumors
CN103088433B (zh) * 2011-11-02 2014-09-24 深圳华大基因科技服务有限公司 全基因组甲基化高通量测序文库的构建方法及其应用
US10077474B2 (en) * 2012-05-29 2018-09-18 Abbott Molecular, Inc. Method of designing primers, method of detecting single nucleotide polymorphisms (SNPs), method of distinguishing SNPs, and related primers, detectable oligonucleotides, and kits
US10260103B2 (en) * 2012-11-27 2019-04-16 Pontificia Universidad Catolica De Chile Compositions and methods for diagnosing thyroid tumors
CN105247073A (zh) * 2013-03-14 2016-01-13 奎斯特诊断投资股份有限公司 用于检测囊性纤维化病的方法
US10544464B2 (en) * 2013-03-27 2020-01-28 The Johns Hopkins University TERT promoter mutations in cancer
NZ630776A (en) * 2013-08-23 2018-09-28 Agriculture Victoria Serv Pty Method of nucleic acid fragmentation
EP3044324A1 (en) * 2013-09-13 2016-07-20 Life Technologies Corporation Classification and actionability indices for cancer
WO2015153808A1 (en) * 2014-04-01 2015-10-08 The Johns Hopkins University Tert and braf mutations in human cancer
CN105200134A (zh) * 2015-09-18 2015-12-30 杭州泛生子医学检验所有限公司 检测人类tert基因启动子突变的方法及其试剂盒
CN108315424B (zh) * 2018-04-10 2021-08-06 广东省人民医院(广东省医学科学院) 甲状腺结节良恶性相关基因的pcr特异性引物、检测试剂盒及检测方法

Also Published As

Publication number Publication date
US20210324468A1 (en) 2021-10-21
US11053542B2 (en) 2021-07-06
WO2017117523A1 (en) 2017-07-06
EP4246144A2 (en) 2023-09-20
CN108699553B (zh) 2023-08-04
EP3397766A1 (en) 2018-11-07
EP3397766B1 (en) 2023-05-17
CA3010013A1 (en) 2017-07-06
EP4246144A3 (en) 2023-12-20
EP3397766A4 (en) 2019-10-02
MX2018008197A (es) 2019-02-20
CN108699553A (zh) 2018-10-23
US20190112653A1 (en) 2019-04-18
BR112018013430A2 (pt) 2018-12-18

Similar Documents

Publication Publication Date Title
MX2022012384A (es) Composiciones y metodos para cribar mutaciones en el cancer de tiroides.
WO2016138105A3 (en) Assays to determine dna methylation and dna methylation markers of cancer
MY195999A (en) Molecular Detection/Diagnosis Reagent for Tumor
MX358117B (es) Métodos y ácidos nucleicos para determinar el pronóstico de un sujeto con cáncer.
WO2014116729A3 (en) Haplotying of hla loci with ultra-deep shotgun sequencing
EP4242329A3 (en) Use of markers including filamin a in the diagnosis and treatment of prostate cancer
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
EP4303314A3 (en) Polypeptide tagged nucleotides and use thereof in nucleic acid sequencing by nanopore detection
PH12018550037A1 (en) Quencher containing water-soluble polymer-conjugated nanomaterial and use thereof
WO2015071669A3 (en) Materials and methods for diagnosis and prognosis of liver cancer
WO2015153732A8 (en) Use of double-stranded dna in exosomes: a novel biomarker in cancer detection
WO2012109157A3 (en) Bioprobes and methods of use thereof
BR112017025254A2 (pt) ?métodos para detecção de pelo menos uma mutação em uma pluralidade de genes relacionados ao câncer, selecionar um indivíduo para tratamento e prever a probabilidade de capacidade de resposta ao tratamento?
MX2018009304A (es) Metodos de diagnostico y pronostico para episodios y enfermedades cardiovasculares.
JP2014144959A5 (es)
WO2015052583A3 (en) Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer
WO2016130572A3 (en) Methods of determining levels of exposure to radiation and uses thereof
AU2015308620A8 (en) Early lung cancer detection by DNA methylation phenotyping of sputum-derived cells
WO2019094780A3 (en) Non-coding rna for detection of cancer
MX2019007894A (es) Composiciones y metodos para detectar el adn tumoral circulante.
EA201691682A1 (ru) Способы анализирования редких циркулирующих в крови клеток
WO2016034715A3 (fr) Methode de prediction de l'evolution clinique du cancer colorectal
EP3825416A3 (en) Gene expression profiles associated with sub-clinical kidney transplant rejection
WO2015120482A3 (en) Recurrent fusion genes identified in high-grade serous ovarian carcinoma
CA2863427A1 (en) Use of pdgfr-.alpha. as diagnostic marker for papillary thyroid cancer